Lenalidomide

Lenalidomide is a derivative of the immunomodulatory compound thalidomide (Cay-14610). It reduces TNF-alpha production in isolated human peripheral blood mononuclear cells (PBMCs) and whole blood stimulated by LPS from S. minnesota (Cay-23608, IC50s = 13 and 25 nM, respectively). Lenalidomide has been used as a building block in the synthesis of PROTACs that induce the degradation of Ikaros family zinc finger protein 1 (IKZF1) and IKZF3 in MM.1S multiple myeloma cells. Orally administered lenalidomide (250 mg/kg per day) reduces vascularization and total microvascular length in a rat mesenteric window assay. Formulations containing lenalidomide have been used in the treatment of myelodysplastic syndrome and multiple myeloma.Formal Name: 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione. CAS Number: 191732-72-6. Synonyms: CC-5013. Molecular Formula: C13H13N3O3. Formula Weight: 259.3. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 16 mg/ml, DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml, DMSO: 16 mg/ml. lambdamax: 206, 220, 311 nm. SMILES: NC1=C(CN(C2C(NC(CC2)=O)=O)C3=O)C3=CC=C1. InChi Code: InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18). InChi Key: GOTYRUGSSMKFNF-UHFFFAOYSA-N.